Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05276219

Optimized Treatment of Pulmonary Edema or Congestion

Background:

Intravenous (IV) loop-diuretics have been a key component in treating pulmonary edema since the nineteen sixties and has a Class 1 recommendation in the 2021 European Society of Cardiology guidelines for heart failure. Conversely, vasodilation was downgraded in the treatment of acute heart failure due to a lack of trials that compare vasodilation with loop-diuretics in a hyperacute clinical setting. This clinical equipoise will be tested in a trial including patients with pulmonary congestion immediately at hospital admission.

Primary objective:

To determine the superior strategy of loop-diuretics (furosemide), vasodilation (nitrates) or the combination during emergency treatment.

Design: Investigator-initiated, randomized, double-blinded, placebo-controlled trial with 1:1:1 allocation.

Intervention:

Intervention-phase will last 6 hours from study-inclusion, and patients will be allocated to one of three groups:

* Boluses of 40 mg IV furosemide + nitrate-placebo as soon as possible and repeated up to 10 times. * Boluses of 3 mg IV isosorbide dinitrate + furosemide-placebo as soon as possible. * Boluses of both 3 mg IV isosorbide dinitrate + of 40 mg as soon as possible.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Bispebjerg Hospital, Copenhagen, Denmark

Loading trial locations.

About this study

IV-loop diuretics are a central part of acute treatment of pulmonary edema and is recommended in guidelines (Class 1 recommendation) with a higher recommendation as compared to vasodilation, which was downgraded from Ia to IIb in the 2021 guidelines for heart failure. However, the effects of loop-diuretics alone or in combination with nitrates compared to nitrates alone is unknown and should be investigated in adequately powered prospective trials to optimize acute treatment of these patients.

Trial objective The primary objective is to determine the superior strategy of urgent treatment (starting within 3 hours after hospital-admission) of pulmonary edema. Strategies are: 1. Diuretics (Furosemide), 2. Vasodilation (nitrates), 3. A combination of both furosemide and nitrates. Patient-outcome will be evaluated through the primary endpoint as described elsewhere.

Hypothesis:

Iv nitrates in combination with iv furosemide are superior compared to iv furosemide alone or iv nitrates alone during initial (first 6 hours) in-hospital treatment of pulmonary edema. "Superior" is defined as a significant benefit on the primary outcome.

Study design The study is an investigator-initiated, randomized, placebo-controlled, double-blinded, multicenter, interventional, clinical trial. Following successful completion of screening procedures, patients will be randomized in a 1:1:1 fashion to receive either of the 3 treatments-strategies.

Since patients are in cardio-respiratory and mental stress, informed consent prior to the intervention will be impossible. Instead, a legal guardian will be contacted and asked for consent in addition to next of kind and patients regaining mental ability.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Acute (within minutes to days) onset or worsening of subjective dyspnea*
  • Systolic blood pressure ≥100 mmHg
  • Oxygen saturation <94% or need of oxygen
  • Signs or suspicion of congestion (peripheral edema, rales, and/or clinical suspicion of congestion) *
  • by the best assessment from a medical doctor. Inclusion must not wait on x-ray or other measures: patients suspected of pulmonary congestion should be included immediately.

Exclusion criteria

  • More than 40 mg IV furosemide within the last three hours before randomization including prehospital treatment.
  • More than 3 hours from hospital-admission to randomization
  • Ongoing ventricular taky- or brady-arrythmias or supraventricular arrhythmias with HR > 180 or < 40 bpm.
  • Suspected severe infection or sepsis.

Exclusion criteria

are purposely liberal, so patients can be included in accordance with everyday clinical practice. However, a safety criterion will be implemented:

If blood pressure drops below 90 mmHg in 2 measurements with 5 minutes apart and/or if urine production is below 50 ml after 1 hour, the intervention will be stopped, and patients can receive furosemide and nitrates freely.

We purposely chose not to exclude patients with aortic stenosis, since observational studies did not find excess risk of given nitrates to patients with pulmonary edema and aortic stenosis

Treatment and study plan

Furosemide Injection

Drug

A diuretic (iv furosemide) strategy for decongestion in acute heart failure

Isosorbide Dinitrate

Drug

Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure

Furosemide and isosorbide dinitrate

Drug

Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure

Primary outcomes

  1. Days alive and outside hospital

    Time frame: 30 days

    The primary end point is the number of days alive and out of hospital during the 30-day period after the hospital-visit. The choice of this end point allow capturing the burden of acute heart failure in terms of mortality, hospital length of stay, and early readmission to the hospital. Patients who died before day 30 will be counted as having zero days alive and out of hospital. A return visit to the emergency department was considered as 1 day in the hospital, using the same approach as a recent trial of acute heart failure.

Secondary outcomes

  1. Intensification of therapy defined as at least one of: mechanical ventilation, renal replacement therapy, vasopressors, inotropes, or mechanical heart failure treatment.

    Time frame: 30 days

  2. Clinical benefit at 30 days, consisting of a composite of 1. All-cause death, 2. Intubation with mechanical ventilation, and 3. rehospitalization, assessed using a 'win-ratio' approach.

    Time frame: 30 days

  3. NT-proBNP at day 1-3

    Time frame: 30 days

  4. Early Warning Score measured 6-24 hours after start of intervention.

    Time frame: 24 hours

  5. Adverse events

    Time frame: 30 days

    An adverse event means any untoward medical occurrence in a subject to whom a medicinal product is administered, and which does not necessarily have a causal relationship with this treatment.

    Adverse events (AE) will be categorized according to the definitions below. To assess specific adverse events possibly related to the trial intervention, we will collect data on the following during the first 24 hours after inclusion in the trial:

    • Symptomatic hypotension needing medical therapy
    • Renal impairment: Need for continuous renal replacement therapy or intermittent hemodialysis
    • Electrolyte disorders: Hypokalemia (<2.5 mM), hyperkalemia (>6.0 mM)
    • Cardiac arrhythmias: VF, VT and AF requiring DC conversion, new need for pacing
    • Respiratory: Intubation and mechanical ventilation during admission
    • Headache requiring treatment,
    • Loss of hearing
    • Anaphylaxis
  6. Patient-reported dyspnea assessment after 12-24 hours (7-point Likert scales in a standardized position: marked improvement from admission = 3, moderate improvement = 2, slight improvement = 1, no change = 0, slight worsening = -1, moderate worsening = -

    Time frame: 24 hours

Other outcomes

  1. Echocardiographic substudy

    Time frame: 72 hours

    parameters at day 0-3: LVEF, TAPSE, TR-gradient, VCI-size and compressibility, e/é. At Hvidovre and Bispebjerg sites, a transthoracic echocardiography will be performed at 12-72 hours after randomization.

    o Multiple B-lines in at least two areas on lung ultrasound identifying interstitial syndrome (yes/no) after 12-72 hours.

  2. Research biobank-parameters

    Time frame: 24 hours

    IL-6, IL-10, copeptin, Soluble CD146 [43], carbohydrate antigen-125 [44], adrenomedullin [45], NT-proBNP [46], Neutrophil gelatinase-associated lipocalin (NGAL) [47]. Several biomarkers will be analyzed from the research biobank. Blood will be collected at admission day 1 (T24). The research biobank will be analyzed for biomarkers of inflammation, organ injury and other organ specific markers. The research biobank will only be collected at Bispebjerg and Hvidovre sites.

  3. FiO2, Blood pressure, respiratory rate, heart rate after 1 hour

    Time frame: 1 hours

  4. Myocardial infarction within 48 hours

    Time frame: 2 days

    Assessed by the treating clinician

  5. FiO2, Blood pressure, respiratory rate, heart rate after 6 hours

    Time frame: 6 hours

  6. Number of patients where intervention is terminated (opt out) before 6 hours

    Time frame: 1 day

  7. All-cause mortality,

    Time frame: 30 days

  8. Days alive out-of-ICU

    Time frame: Day 30

  9. Change from inclusion to t24 in creatinine and CRP at the next day after inclusion.

    Time frame: 24 hours

Study contacts

Contact information is provided by the study sponsor or research team.

Jens Jakob Thune, MD, PhD

CONTACT

[email protected]

Johannes Grand, MD, Phd, MPH

CONTACT

[email protected]

+4535452121

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • Bispebjerg Hospital
  • Copenhagen University Hospital, Hvidovre
  • Herlev Hospital
  • Zealand University Hospital

Registry information

Official study title

Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial

Acronym: Decongest

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Mar 11, 2022
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.